Connect with us

Digital Health

PharmaForceIQ’s AI-Driven Omnichannel Platform Boosts HCP Engagement and NRx by 97%

PharmaForceIQ, an AI-driven omnichannel platform for hyper-targeted HCP marketing, announced impressive results from a 24-month HCP campaign for a 2nd…

Published

on

This article was originally published by AITHORITY
PharmaForceIQ’s AI-Driven Omnichannel Platform Boosts HCP Engagement and NRx by 97%

PharmaForceIQ, an AI-driven omnichannel platform for hyper-targeted HCP marketing, announced impressive results from a 24-month HCP campaign for a 2nd to market NSCLC drug in which Medscape (WebMD) was leveraged as one of the high performing channels.

PharmaForceIQ was founded to integrate & orchestrate the entire life sciences HCP marketing ecosystem. In 2020, the company initiated a project for a rare 2nd to market NSCLC targeted therapy which had limited marketing resources and a small sales team, hence was looking to optimize its HCP targeting efforts i.e., increase its HCP share of voice (SOW) when it matters most.

Recommended AI: Lion Announces It Will Explore ChatGPT Related AI & NLP Technologies To Empower Digital Program

PharmaForceIQ partnered with Medscape and other 3rd party partners to deliver the “Right Message, at the Right Time, to the Right Physician via the Right Channel “by:

  • Identifying and characterizing patients and treating HCP targets in “Real Time” via the use of real-world data (RWD) i.e., “triggers”
  • Developing customized message sequences based on the different HCP archetypes and their channel preferences
  • Deploying the HCP triggers in an omnichannel way based on physician affinity across sales rep CRM (Veeva), digital, peer to peer and through 3rd party endemic digital partners (including Medscape’s Next Best Engagement program)
  • Integrating all of the above in a near real-time dashboard that monitored performance metrics and triggered next best actions

Among the soon to be published results, HCP engagement rates for the brand more than doubled compared to the industry standard during the first 12 months of implementation, and has remained consistent over an ongoing period of 24 months. The Medscape NBE channel was the highest performing platform across the 3rd party partners in terms of overall engagement rates, accounting for about 45% of engagements in the first 12 months. As a testament to the hyper-targeted omnichannel approach, 97% of all new patient referrals (NRx) in year 1 of launch were traced and attributed directly back to the triggers and engagements generated from the PharmaForceIQ platform.

Recommended AI: QuickLogic Drives eFPGA Innovation with New Aurora Development Tool Suite

“These results mean the brand was able to focus and track its physician marketing efforts to when it matters most i.e., when a physician has a potential patient, without sacrificing SOV with target HCPs and prescription opportunities,” said Stephen Onikoro, Senior Principal at PharmaForceIQ. “The power of this approach is in the ability to target each individual HCP anywhere in the ecosystem whether endemic, non-endemic, sales rep CRM or peer to peer events”

“Our partnership with PharmaForceIQ on the Next Best Action Omnichannel project provided a real-world case study of the performance of Medscape’s Next Best Engagement approach. We were thrilled to have 97% of the brand’s first year’s NRx attributed back to our combined efforts” said Young Hur, Associate Director, Commercial Clinical Strategy” said Young Hur, Associate Director, Commercial Clinical Strategy, Medscape

Recommended AI: Philips Speech and Sembly AI Launch SmartMeeting As Answer To New Meeting Culture

[To share your insights with us, please write to sghosh@martechseries.com]

The post PharmaForceIQ’s AI-Driven Omnichannel Platform Boosts HCP Engagement and NRx by 97% appeared first on AiThority.


prescription

Digital Health

Keep it Short

By KIM BELLARD OK, I admit it: I’m on Facebook. I still use Twitter – whoops, I mean X. I have an Instagram account but don’t think I’ve ever posted….

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading
Digital Health

Seattle startup Olamedi building platform to automate health clinic communications

A new Seattle startup led by co-founders with experience in health tech is aiming to automate communication processes for healthcare clinics with its software…

Continue Reading

Trending